DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Lammers PE, Dank M, Masetti R. et al.
A randomized, double-blind study of PF-05280014 (a potential biosimilar) vs. trastuzumab, both given with docetaxel (D) and carboplatin (C), as neoadjuvant treatment for operable human epidermal growth factor receptor 2-positive (HER21) breast cancer.
Ann Oncol 2017;
28 (Suppl. 05) v43-v67 Abstr. 154PD
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.